FAS and chronic myelogenous leukemia, BCR-ABL1 positive: Shlomchik and Pear [10] reported that the GVL effect is not reduced in Fas-deficient mice, which implies that the TRAIL/death receptor interaction might influence the elimination of immune-mediated CML malignant cloning.